A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC).
AffiliationCRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, UK.
MetadataShow full item record
AbstractFor the first time in a clinical study oral Ifosfamide was used: 65 elderly or unfit patients with small cell lung cancer (SCLC) were treated as outpatients with fractionated oral Ifosfamide and Etoposide. Forty patients (62%) had extensive stage (ED) disease. The median age of the patients was 66 years. In the 60 patients evaluable for response the objective response rate was 90% with a complete response (CR) rate of 32% and a partial response (PR) rate of 58%. The overall median survival of all 65 patients was 11 months (13 months for LD, 9.5 months for ED). In those patients with LD achieving a CR or a PR radiotherapy was given to the mediastinum. No prophylactic cranial irradiation was given. There was a rapid improvement in the responding patients' performance status and symptoms generally with the first treatment cycle. Overall haematological toxicity was mild, with intravenous antibiotics only being required in 4% of the courses and with only one treatment-related death from septicaemia. A higher than expected rate of CNS toxicity was seen (30%). This was generally mild and always fully reversible and consisted mainly of forgetfulness, occasionally hallucinations, nightmares and somnolence. In only one case did encephalopathy necessitate early termination of treatment. This raises the question of whether Ifosfamide metabolism differs quantitatively or qualitatively when given by the oral route as opposed to the usual intravenous route. We conclude that this simple outpatient based treatment gives a high response rate with rapid improvement in symptoms.
CitationA simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC). 1989, 60 (2):258-61 Br. J. Cancer
JournalBritish Journal of Cancer
- Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
- Authors: Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Wenger M, Lange W, Mertelsmann R
- Issue date: 1997 Jan
- Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
- Authors: Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H
- Issue date: 1989 Feb
- Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
- Authors: Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Lange W, Mertelsmann R
- Issue date: 1999 May
- Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
- Authors: Unsal M, Erturk D
- Issue date: 2003 Jun
- Experience with ifosfamide and etoposide combination chemotherapy in extensive-disease small-cell lung cancer.
- Authors: Wu MF, Perng RP, Chen YM, Liu JM, Yang SL, Whang-Peng J
- Issue date: 1997 Aug